TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors

European Journal of Cancer and Clinical Oncology

Volumn 26, Issue 3, 1990, Pages 397-404

  Toko, Toshiyuki ^a   Sugimoto, Yoshikazu ^a   Matsuo, Ken Ichi ^a   Yamasaki, Ryouko ^a   Takeda, Setsuo ^a   Wierzba, Konstanty ^a   Asao, Tetsuji ^b   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b NAEJA Pharmaceutical Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; MIPROXIFENE PHOSPHATE; NEW DRUG; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPARATIVE STUDY; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; RATS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0025361621     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(90)90241-K     Document Type: Article

References (32)

1. Hormonal therapy of breast cancer: new approaces and concepts
2. Tamoxifen therapy in premenopausal patients with metastatic breast cancer
3. Clinical evaluation of Tamoxifen for advanced and recurrent breast cancer
4. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer
5. Cellular and molecular mechanism of action of antiestrogens
6. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen
7. The pharmacology and clinical use of tamoxifen
8. The effects of estrogens and antiestrogens of hormone-responsive human breast cancer in long-term tissue culture
9. Hormone dependency and the action of tamoxifen in human mammary carcinoma cells
10. Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
11. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women
12. Tamoxifen in advanced breast cancer
13. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer
14. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer
15. The measurement of tamoxifen and metabolites in the rat and relationship to the response of DMBA-induced mammary tumors
16. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells
17. 3) distinct from the calmodulin-binding site
18. High affinity anti-oestrogen binding site distinct from the oestrogen receptor
19. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients
20. Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model
21. Determination of Tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation
22. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma
23. Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites
24. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
25. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry
26. Antitumor action of Keoxifen and Tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
27. Effect of a new antiestrogen, Keoxifen (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
28. Identification of estrogen receptors in mammary cancer cells by immunofluorescence
29. Anchorage-independent growth-conferring factor production by rat mammary tumor cells
30. Autocrine stimulation by estradiol-regulated growth factors of rat hormone-responsive mammary cancer: interaction with the polyamine pathway
31. Evidence that transforming growth factor-B is a hormonally regulated negative growth factor in human breast cancer cells